Personnes associées (29)
Didier Trono
Après des études de médecine à l’Université de Genève et une formation clinique en pathologie, médecine interne et maladies infectieuses à Genève et au Massachusetts General Hospital de Boston, Didier Trono s’engage dans une carrière scientifique au Whitehead Institute du MIT. En 1990, il est recruté par le Salk Institute de San Diego pour lancer un centre de recherche sur le SIDA. Il rentre en Europe sept ans plus tard, avant de prendre en 2004 les rênes de la toute nouvelle faculté des Sciences de la Vie de l’EPFL, dont il orchestre le développement et qu’il dirige jusqu’en 2012. Il participe aujourd’hui activement à la coordination des efforts de la Suisse en vue de l’intégration des nouvelles technologies dans le domaine de la médecine de précision et de la santé personnalisée.
Florian Maria Wurm
Florian Wurm received his academic training as a Biologist and Molecular Geneticist at the University of Giessen. He joined the Hoechst AG (Behringwerke) in Marburg as head of a laboratory in Virology. Working with immortalized mammalian cells for the establishment of production processes for alpha-interferons provided the first opportunity to combine basic research with medical application. In 1984 he joined Harvard Medical School in Boston as a Research Fellow in Molecular Biology. 1986 he took an offer from Genentech Inc. in San Francisco to work in Process Sciences on the development of large scale manufacturing processes for recombinant proteins. There he has held a number of leading positions and has acquired intimate knowledge in the generation of protein pharmaceuticals in mammalian cells in bioreactors (a number of which are now marketed products).  In 1995 he joined the EPFL as a Professor for Biotechnology. Wurm has published more than 250 scientific papers and holds more than 20 patents/patent-applications. His H-index stands at 60 in 2021.  He was Chairman (2005-2009) and is member of the Executive Board of the European Society of Animal Cell Technology (ESACT). He serves as a consultant to the pharmaceutical Biotech Industry, mainly in the fields of animal cell technology for recombinant protein production and in regulatory affairs. He works as a scientific reviewer and editior/asscciate editor for a number of international journals in the Biotech field. F.M. Wurm teaches classes to pre- and postgraduate students in the fields of Molecular and Cellular Biotechnology. He was founder and Chief Scientific Officer of ExcellGene SA, a 2001 established company in Monthey, Switzerland. He took the position of President and CEO of ExcellGene in 2015. He retired from the CEO position in 2017 and continues to be President and Chief Scientific Officer of ExcellGene. In 2008 Dr. Wurm was appointed Visiting Professor for Biotechnology at Jinan University in Guangzhou, China.   He retired from his position at the EPFL in 2015. His laboratory is closed. With his team at ExcellGene and in collaboration with Dr. Paco Pino, Director of R&D, he continues to explore manufacturing sciences with animal cells in bioreactors.
Pierre Gönczy
Pierre Gönczy obtained his PhD from The Rockefeller University (New York, USA) in 1995 and joined the laboratory of Tony Hyman at the EMBL (Heidelberg, Germany) as a postdoctoral fellow in 1996. He started his own laboratory at ISREC in 2000. In 2005, he became Associate Professor at the EPFL School of Life Sciences, and was promoted Full Professor in 2009.
Patrick Aebischer
Patrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse. De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé. En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne. En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de l’EPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016. Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe qu’aux Etats-Unis. Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs. Les recherches qu’il poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
Matthias Lütolf
Matthias Lutolf is Full Professor at EPFL’s Institute of Bioengineering, with a cross appointment in the Institute of Chemical Sciences and Engineering. Lutolf was trained as a Materials Engineer at ETH Zurich where he also carried out his PhD studies (with Jeffrey Hubbell) that were awarded with an ETH medal. He continued his research training as a Post-Doctoral Fellow in Stem Cell Biology (with Helen Blau) at Stanford University. He has served as the Director of the Institute of Bioengineering from 2014 to 2018. Lutolf is an internationally recognized leader in the fields of stem cell bioengineering and tissue engineering. His research program uniquely combines stem cell biology with engineering principles and quantitative thinking. His team, composed of engineers, chemists, physicists, cell and developmental biologists, strives to develop technologies that have true biological and medicinal function and applicability. Lutolf’s work has led to more than 110 peer-reviewed scientific publications, many of which published in highly reputed journals, more than 25 patents, and the commercialization of several products. Current research in the Lutolf lab is focused on the bioengineering of miniature tissues, termed organoids, that are generated from self-organizing stem cells.
Yann Barrandon
Yann Barrandon graduated in Medicine in Paris where he also trained as a dermatologist and completed his PhD “on the long term cultivation of human haematopoietic stem cells” in 1982 under the direction of Dr. Catherine Dresch (Centre Hayem, St Louis Hospital). He worked as a post-doctoral fellow (1982-1983) with Pr. Marvin Karasek in the Department of Dermatology at Stanford University CA, and then with Pr. Howard Green, a pioneer in cell therapy, in the Department of Molecular and Cellular Physiology at Harvard Medical School (1983-1990). During this period, he participated in the world's first transplantations of epidermal stem cells on extensive third degree wounds and contributed several seminal findings including the demonstration of stem cells in cultures of human keratinocytes (PNAS 1987), and that human keratinocyte stem cells could be efficiently transduced by retroviral vectors (Science 1987), in collaboration with Richard Mulligan at the Whitehead Institute for Biomedical Research (Massachussets Institute of Technology, Cambridge, USA). He has also participated to the transfer of the stem cell technology from Harvard University to a spin off biotechnology company, now part of Genzyme Corp. He returned to France in 1990 as Director of Research at the INSERM and Head of Lab at the Ecole Normale Supérieure, Paris. During this period, he demonstrated the presence of multipotent clonogenic stem cells in hair follicles (Cell 1994, 2001) and successfully brought stem cells from bench to bedside demonstrating the usefulness of a fibrin matrix to transplant epidermal stem cells. (Transplantation, 2000). Following his move to Lausanne, Yann Barrandon has shown that oligopotent stem cells are present in the mammalian cornea (Nature 2008), challenging previous dogma. He has also contributed to the characterisation of several skin diseases (Nature Genetics, 1993a, 1993b, 2000, 2005) and towards gene therapy of dystrophic epidermolysis bullosa. He is a partner in several EEC stem cell consortia (FP6: Therapeuskin and EuroStemCell, FP7: EuroSyStem, OptiStem, BetaCellTherapy). Current research targets the role of small microenvironmental variations on stem cell behavior, and exploring the potency of stem cells of stratified epithelia (skin, esophagus, ocular surface) and of thymic epithelial cells. The lab is also involved in understanding the factors that regulate stem cell engraftment to improve epithelial cell therapy. An important aspect of the research aims at setting up a pilot clinical trial to demonstrate the feasibility of ex vivo gene therapy to treat Dystrophic Epidermolysis Bullosa, a rare but horrendous congenital disease of the skin that results in continuous blistering of the skin, chronic wounds, fusion of fingers and development of carcinoma. Yann Barrandon was a member of the Faculty Council of the EPFL School of Life Sciences 2006-2008, of the Board of Swiss Stem Cell Network, 2004-2009, and is a member of the EPFL Ethics Committee since 2008. He is a reviewer for major scientific journals and for major granting agencies abroad. He is a member of the board of Directors of the International Society for Differentiation (ISD) and of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) and was a Member of the Board of Directors of the European Tissue Repair Society, 1990-1995. He was elected as EMBO member in 2009. He has given over 300 invited conferences and seminars worldwide on the biology and the therapeutic use of cutaneous stem cells including: Gordon Research Conferences, Tissue Repair and Regeneration, June 2005, New London, USA, Keystone Symposia on Stem Cells, April 2006, Whistler, Canada Keystone Symposia, Stem Cell Interactions with their Microenvironmental Niche, March 2007, Keystone, USA Keystone Symposia, Stem Cell Niche Interactions, April 2009, Whistler, Canada Gordon Research Conferences, Epithelial Stem Cells, June 2009, Les Diablerets, Switzerland 7th Meeting of the International Society Stem Cell Research, July 2009, Barcelona, Spain 16th International Society for Developmental Biologists, Edinburgh, Scotland, UK, Sept 2009 Yann Barrandon has given multiple media interviews and participated to different reportages: LCI, TF1, France 2, France 3, RSR (Radio Suisse Romande), TSR (Television Suisse Romande), and articles in newspapers: Figaro, La Croix, Le Temps, L’Hebdo, Le Nouvelliste, etc. He was also a participant in the movie “A Stem Cell Story”, EuroStemCell, Best TV/video production, Tromsø Science Media Festival; Best short film, Scinema (Australia); In competition, Science Film Festival (Bangkok), BaKaFORUM 2007, Vedere la Scienza He organized the second EuroStemCell international conference “Advances in Stem Cell Research” supported by the EMBO and held in Lausanne 8-10 September 2006. He regularly participates as faculty to the EEC funded Stem Cell Summer School held in Hydra Greece since 2005.
Paul Joseph Dyson
Paul Dyson rejoignit l’EPFL en 2002 à la tête du Laboratoire de chimie organométallique et médicinale de l’Institut des sciences et ingénierie chimiques, dont il en assuma ensuite la direction entre 2008 et 2016. Le prof. Dyson  a été récompensé par de nombreux prix dont le Prix Werner de la Société Suisse de Chimie en 2004, le Prix pour les réalisations exceptionnelles en chimie bio organométallique en 2010, la Médaille du Centenaire de la naissance de Luigi Sacconi (2011) de la Société Italienne de Chimie, le Prix de Chimie bio-inorganique de la Royal Society of Chemistry en 2015, le Prix européen pour une chimie durable de la Société Européenne de Chimie en 2018 et le Prix pour la chimie verte de la Royal Society of Chemistry en 2020. Le prof. Dyson est également mentionné dans la liste établie par Clarivate des chercheurs les plus cités (Clarivate Highly Cited Researcher), avec un H-index >110 (Web of Science et Google Scholar). Paul Dyson a été élu membre de la Royal Société de Chimie en 2010, membre de l’Académie Européenne des Sciences en 2019 et membre à vie de l’Association Américaine pour l’Avancement de la Science en 2020. Au cours des dernières années il s’est vu décerner le titre de Professeurs Hôte par l’Université de Bourgogne,  l’Université de Pierre et Marie Curie,  l’Université de Vienne,  l’Université de Rome Tor Vergara, l'Ecole Nationale Supérieure de chimie de Paris (Chimie ParisTech) et par l’Université de Shangai Jiao Tong. De 2016 à 2021 il était membre du conseil de la recherche de la division de mathématique, sciences naturelles et de l’ingénieur du Fonds National Suisse.  En 2021, il a été nommé doyen de la Faculté des Sciences de Base.
Priscilla Turelli
Positions 2005-présent: Chercheur, Ecole Polytechnique Fédérale de Lausanne, Laboratoire de virologie et génétique, Suisse. 2001-2004: Chercheur dans le laboratoire du Pr D. Trono, Département de Microbiologie, Ecole de Médecine de Genève, Suisse. 1997-2001: Etudiante Post-doctorante dans le laboratoire du Pr D. Trono, Département de Microbiologie, Ecole de Médecine de Genève, Suisse.
Honneurs et prix 2004: Bristol-Myers Squibb AIDS AWARD 1997-1999: Human Frontier Science Program fellowship
Education June 1997: PhD in cellular biology. Final mark:jury congratulations. Université de la Méditerranée, France. June 1993: Post-graduate diploma in cellular biology and microbiology. INSERM U372, Marseille-Luminy, université de Provence, France. June 1992: Master in cellular biology – Specialty: genetic. Final mark: Best master student of this year. Université de la Méditerranée, France. June 1987: Scientific baccalaureate, France.
Enseignement 2009-présent: co-directeur de thèses, Ecole Polytechnique Fédérale de Lausanne, Suisse 2002: Tuteur en virologie pour les étudiants de médecine, Ecole de Médecine de Genève, Suisse. 1996-1997: Tuteur en biologie moléculaire et biochimie, Université de la Méditerranée, Aix Marseille II

Graph Chatbot

Chattez avec Graph Search

Posez n’importe quelle question sur les cours, conférences, exercices, recherches, actualités, etc. de l’EPFL ou essayez les exemples de questions ci-dessous.

AVERTISSEMENT : Le chatbot Graph n'est pas programmé pour fournir des réponses explicites ou catégoriques à vos questions. Il transforme plutôt vos questions en demandes API qui sont distribuées aux différents services informatiques officiellement administrés par l'EPFL. Son but est uniquement de collecter et de recommander des références pertinentes à des contenus que vous pouvez explorer pour vous aider à répondre à vos questions.